Skip Navigation


European Heart Journal Advance Access originally published online on February 4, 2009
European Heart Journal 2009 30(5):524-525; doi:10.1093/eurheartj/ehp027
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
30/5/524    most recent
ehp027v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Sajadieh, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sajadieh, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org

A new combination therapy in stable angina pectoris

Ahmad Sajadieh*

Department of Cardiology, Bispebjerg University Hospital of Copenhagen, Bispebjerg Bakke 23, 2400 Copenhagen NV, Denmark

* Corresponding author. Tel: +45 35 31 33 33, Fax: +45 35 31 32 26, Email: ahs@dadlnet.dk

This editorial refers to ‘Efficacy of the If current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial’{dagger}, by J.-C. Tardif et al. on page 540

The first 10% of the full text of this article appears below.

Ischaemic heart disease is the leading cause of death in high, middle, and low income countries.1 The improvement in management and survival of heart disease in the last decades, together with an increasingly ageing population, continues to increase the absolute number of patients with heart disease.1,2 Optimal medical therapy includes satisfactory antianginal therapy and intensive risk factor modification as the first-line treatment in the majority of cases.3 This very large group of patients presents with a natural diversity with regard to symptoms, side effects of medications, . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Efficacy of the If current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial
Jean-Claude Tardif, Piotr Ponikowski, Thomas Kahan, and for the ASSOCIATE study Investigators
EHJ 2009 30: 540-548. [Abstract] [FREE Full Text]  



This article has been cited by other articles:


Home page
 Postgrad. Med. J.Home page
J M Wilson
Diagnosis and treatment of acquired coronary artery disease in adults
Postgrad. Med. J., July 1, 2009; 85(1005): 364 - 365.
[Abstract] [Full Text] [PDF]